XenoPort to Release Third Quarter Financial Results on November 4
October 23 2014 - 10:00AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
release its third quarter financial results on November 4, 2014 at
approximately 4:30 p.m. Eastern Time. The company will host a
conference call at 5:00 p.m. Eastern Time that same day to provide
a summary of its financial results and general business updates. A
replay of the call will be available for one week following the
event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial 888-275-3514.
International callers may access the live call by dialing
706-679-1417. The reference number to enter the call is
15141774.
A replay of the conference call will be available for one week
following the event and may be accessed after 8:00 p.m. Eastern
Time that same day via the Internet, at www.XenoPort.com, or via
phone at 855-859-2056 for domestic callers, or 404-537-3406 for
international callers. The reference number to enter the replay of
the call is 15141774.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and/or relapsing
forms of multiple sclerosis. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort granted exclusive world-wide rights for the
development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Reckitt Benckiser
Pharmaceuticals, Inc. for all indications. XenoPort's pipeline of
product candidates also includes a potential treatment for patients
with Parkinson's disease. To learn more about XenoPort, please
visit the Website at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2F
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024